Odonate Inc (ODTC) Stock Price, Trades & News

	Name	Value
	Revenue (TTM) (Mil $)
	EPS (TTM) ($)	-
	Beta	0.0937
	3-Year Sharpe Ratio	0.11
	3-Year Sortino Ratio	0.25
	Volatility %	-
	14-Day RSI	-
	14-Day ATR ($)	-
	20-Day SMA ($)	150000
	12-1 Month Momentum %	-
	52-Week Range ($)	150000 - 150000
	Shares Outstanding (Mil)

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	0
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Odonate Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Odonate Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings results for 2026	2026-11-13	In 117 days
Second quarter earnings results for 2026	2026-08-14	In 26 days
First quarter earnings results for 2026	2026-07-22	In 3 days
General meeting for 2025	2026-07-22	In 3 days
Annual report for 2024	2025-03-19	150,000.00 (+0.00%)
Fourth quarter earnings results for 2024	2025-02-28	150,000.00 (+0.00%)
0.125:1 Stock Split	2025-01-15	176,040.00 (+7.34%)
Third quarter earnings results for 2024	2024-11-29	136,400.00 (+0.00%)
Second quarter earnings results for 2024	2024-08-30	136,400.00 (+0.00%)
0.2:1 Stock Split	2024-04-09	140,000.00 (+0.00%)

Show

Entries

Odonate Inc Frequently Asked Questions

What is Odonate Inc(ODTC)'s stock price today?

The current price of ODTC is $150000.00. The 52 week high of ODTC is $150000.00 and 52 week low is $150000.00.

When is next earnings date of Odonate Inc(ODTC)?

The next earnings date of Odonate Inc(ODTC) is 2026-07-22 Est..

Does Odonate Inc(ODTC) pay dividends? If so, how much?

Odonate Inc(ODTC) does not pay dividend.

Guru Commentaries on OTCPK:ODTC

No articles.

Press Release

	Subject	Date
	Odonate Announces Expected Delisting of Its Stock	2022-01-07
	ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Odonate Therapeutics, Inc. - ODT	2021-12-10
	Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan	2021-11-17
	ODONATE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Odonate Therapeutics, Inc. - ODT	2021-08-20
	SHAREHOLDER ALERT: Odonate Therapeutics, Inc. (ODT) Officers and Directors Under Investigation for Possible False Statements to Investors	2021-08-13
	The Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of Investors	2021-08-06
	Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)	2020-12-11
	Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast Cancer	2020-12-07
	Odonate Therapeutics to Host Virtual Investor and Analyst Event on December 11, 2020	2020-12-01
	DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Odonate Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm	2020-11-16

10/Page

Articles on Odonate Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.